Tenofovir News and Research

RSS

Comparison of antiretroviral therapies shows that tenofovir DF and stavudine are equally effective

Results from a three year double-blinded trial which compared antiretroviral therapies show that the combination regimens of tenofovir DF and stavudine, are equally effective, though tenofovir DF has more favorable outcomes with respect to cholesterol levels and the nervous system.

11 Jul 2004

Relatively difficult for the AIDS virus to develop resistance to the drug, tenofovir, or the DAPY (diarylpyrimidine) family of compounds

HIV is a moving target, unpredictably changing direction to elude anti-AIDS drugs, but researchers at Rutgers are clearly on the track of solutions to combat HIV drug resistance.

29 Jun 2004

Plans for once-daily, fixed-dose combination of three anti-HIV drugs

Bristol-Myers Squibb Company, Gilead Sciences, Inc. and Merck & Co., Inc. have announced that they are in discussions on the development of a once-daily, fixed-dose combination of three anti-HIV drugs and are also considering certain co-packaging options for the individual products.

16 May 2004

Roche announces new dosing strategy

Roche has announced results from a study demonstrating that the new boosted dosing regimen for its protease inhibitor Invirase(R) (saquinavir 1000 mg with ritonavir 100 mg twice-daily) has no significant interactions when it is co-administered with tenofovir disoproxil fumarate (300 mg once-daily).

9 Apr 2004